1. Scrip
  2. >>Business
  3. >>Stock Watch

Stock Watch: Johnson & Johnson’s Q2 Helps Pharma Sentiment

After The Post-Pandemic Sell-Off, Investors Could Be Returning To The Sector

 
• By Andy Smith

Pharmaceutical stocks have underperformed in the year to date, but J&J, Novartis and GSK may have started to turn the worm.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

In the year to the start of second-quarter earnings season, the broad US S&P 500 stock index had risen by nearly 19%. This was partly driven by big technology companies and partly by multiple expansion resulting from investors’ hopes that falling inflation will increase company profits. A notable absentee from this party was the pharmaceutical sector, with the NYSE Arca Pharmaceutical Index (DRG) falling by nearly 2%, while healthcare conglomerate Johnson & Johnson’s (J&J’s) stock price lagged both these indexes with a fall by nearly 10% over the same period.

However, J&J’s second-quarter earnings announcement prompted a greater than 6% stock price rise against the DRG’s rise of just over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

Stock Watch: Q2 Earnings Blowouts Resume At AstraZeneca And GSK

 
• By Andy Smith

While second-quarter revenue growth bolstered both the UK’s big pharma companies, some of that growth may have been catch-up from the weak first quarter. This resulted in sales of even seasonally weak off-patent products, growing.

Stock Watch: Q2 Sales Growth Sparks Diverging Reactions To J&J And Novartis

 
• By Andy Smith

With drug sector indexes underperforming the broad market in the first half of 2025, investors may have been anticipating tariff-related and other headwinds. But impending loss of exclusivity on key products may be provoking more anxiety at this point.

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

More from Business

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis